Anti-PR1 T cells were more prevalent in CML, enriched in bone marrow samples, and enriched in the mature, cytotoxic CD8 + TEMRA cluster, especially in a patient maintaining TFR. This evidence concerns the gene TMEM37 and chronic myelogenous leukemia, BCR-ABL1 positive.